論文 - 藤原 一男
-
Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, EKatz E, Cree BAC.
Neurol Neuroimmunol Neuroinflamm. 8 ( 3 ) e978 2021年5月
-
Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, Okita K, Sasou S, Watanabe M, Namatame C, Matsumoto Y, Ono H, Kaneko K, Nishiyama S, Kuroda H, Nakashima I, Lassmann H, Fujihara K, Itoyama Y, Aoki M.
Brain. 144 ( 8 ) 2401 - 2415 2021年5月
-
Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder.
Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakashima I.
Neurology. 97 ( 1 ) e1 - e12 2021年5月
-
Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: a case report.
Asano T, Saito Y, Matsuoka N, Temmoku J, Fujita Y, Hattori K, Kobayashi S, Ojima A, Takahashi T, Matsumoto H, Yashiro-Furuya M, Sato S, Kobayashi H, Watanabe H, Yano K, Sasajima T, Fujihara K, Migita K.
Medicine (Baltimore). 100 ( 15 ) e24889 2021年4月
-
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group.
Mult Scler Relat Disord. 50 ( 102849 ) 2021年2月
-
Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Akaishi T, Himori N, Takeshita T, Fujihara K, Misu T, Takahashi T, Fujimori J, Ishii T, Aoki M, Nakazawa T, Nakashima I.
Brain Behav. 11 ( 5 ) e02083 2021年2月
-
Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, MD, Pittock, SJ, for the PREVENT Study Group.
Ann Neurol. 89 ( 6 ) 1088 - 1098 2021年2月
-
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E.
Mult Scler. 27 ( 13 ) 2052 - 2061 2021年2月
-
Progression pattern of neurological disability in reference to clinical attacks in anti-MOG antibody-associated disorders.
Akaish T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishi T, Aoki M, Fujihara K, Nakashima I.
J Neuroimmunol 31 ( 351 ) 577467 2021年2月
-
Early Treatment Initiation with Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I.
Front Neurol 22 ( 12 ) 608149 2021年2月
-
Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Nakashima I.
J Neurol 2021年1月
-
CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder.
Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M.
Heliyon 7 ( 1 ) e05899 - e05899 2021年1月
-
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S, on behalf of the PREVENT Study Group.
Mult Scler Relat Disord ( 47 ) 102641 2021年1月
-
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, Fujihara K, Aoki M.
Mult Scler Relat Disord 22 ( 49 ) 102750 2021年1月
-
New therapies for neuromyelitis optica spectrum disorders.
Levy M, Fujihara K. Place J.
Lancet Neurol. 20 ( 1 ) 60 - 67 2021年1月
-
Patterns of cortical grey matter thickness reduction in multiple sclerosis.
Fujimori, Fujihara K, Wattjes M, Nakashima I.
Brain Behav 27 e02050 2021年1月
-
Treatment of MOG Antibody Associated Disorders: Results of an International Survey.
Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintz en RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A.
J Neurol 267 ( 12 ) 3565 - 3577 2020年12月
-
Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
Akaishi T, Fujimori J, Takahashi T, Misu T, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Fujihara K, Nakashima I.
J Neuroimmunol 15 ( 349 ) 577431 2020年12月
-
Distinctive lesions of bran MRI between MOG-antibody-associated and AQP4-antibody-associated diseases.
Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Fujimori J, Nakashima I, Fujihara K, Aoki M.
J Neurol Neurosurg Psychiatry 92 ( 6 ) 2020年12月
-
Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.
Akaishi T, Takshita T, Himori N, Takahashi T, Misu T, Ogawa R, Kaneko K, Fujimori J, Abe M, Ishii T, Fujihara K, Aoki M, Nakazawa T, Nakashima I.
Front Neurol 2 ( 11 ) 932 2020年9月